DCs-based therapies: potential strategies in severe SARS-CoV-2 infection

Int J Med Sci. 2021 Jan 1;18(2):406-418. doi: 10.7150/ijms.47706. eCollection 2021.

Abstract

Pneumonia caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is spreading globally. There have been strenuous efforts to reveal the mechanisms that the host defends itself against invasion by this virus. The immune system could play a crucial role in virus infection. Dendritic cell as sentinel of the immune system plays an irreplaceable role. Dendritic cells-based therapeutic approach may be a potential strategy for SARS-CoV-2 infection. In this review, the characteristics of coronavirus are described briefly. We focus on the essential functions of dendritic cell in severe SARS-CoV-2 infection. Basis of treatment based dendritic cells to combat coronavirus infections is summarized. Finally, we propose that the combination of DCs based vaccine and other therapy is worth further study.

Keywords: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection; dendritic cells (DCs) vaccine; immune system response; immunotherapy; therapeutic vaccine.

Publication types

  • Review

MeSH terms

  • COVID-19 / immunology
  • COVID-19 / therapy*
  • Clinical Trials as Topic
  • Dendritic Cells*
  • Host-Pathogen Interactions
  • Humans
  • Immunotherapy*
  • SARS-CoV-2 / physiology*